IPA‑PXR‑HDAC3 Axis as a Direct Modulator of Epigenetic Aging

Hypothesis

Indole-3-propionic acid (IPA) directly slows epigenetic aging by activating the pregnane X receptor (PXR), which in turn recruits histone deacetylase 3 (HDAC3) to suppress senescence‑associated transcriptional programs, thereby reducing GrimAge and DunedinPACE acceleration.

Mechanistic Rationale

Preclinical work shows IPA extends lifespan in Drosophila and improves muscle/bone health in aged mice via PXR activation and oxidative stress reduction [1]. In humans, low plasma IPA predicts postoperative delirium and Alzheimer’s disease, while centenarians exhibit elevated IPA [2a,2b]. These associations suggest IPA tracks healthy aging, but causality remains untested.

It's plausible that ligand‑bound PXR forms a complex with HDAC3 and the corepressor SMRT, leading to deacetylation of H3K27ac at promoters of SASP genes (e.g., IL6, IL8). This chromatin remodeling diminishes NF‑κB driven inflammation, lowers oxidative stress, and slows the accumulation of epigenetic age markers. Importantly, PXR activation also upregulates Nrf2‑mediated antioxidant response, creating a feed‑forward loop that reinforces the anti‑senescent state.

Testable Predictions

1. In a longitudinal cohort (n≥500) of middle‑aged adults, baseline plasma IPA will inversely predict change in GrimAge and DunedinPACE over 2 years, independent of chronological age, BMI, and baseline inflammation (CRP). Effect size (standardized beta) will be ≥0.15.
2. Ex vivo treatment of peripheral blood mononuclear cells (PBMCs) with physiological IPA concentrations (5‑20 µM) will increase PXR‑HDAC3 co‑immunoprecipitation and reduce H3K27ac at SASP promoters, measurable by ChIP‑qPCR.
3. Pharmacological blockade of PXR (using GSK‑2033) will attenuate IPA‑induced HDAC recruitment and the associated reduction in epigenetic age acceleration in cultured human fibroblasts subjected to oxidative stress.
4. Individuals harboring loss‑of‑function variants in the PXR gene (NR1I2) will show a blunted relationship between IPA levels and epigenetic age change, providing a genetic instrument for Mendelian randomization.

Experimental Design

• Observational arm: Collect fasting plasma, genotype, and PBMCs at baseline and follow‑up; quantify IPA via LC‑MS/MS; compute GrimAge and DunedinPACE from DNA methylation arrays.
• Intervention arm: Randomize a subset to receive oral IPA (500 mg daily) or placebo for 6 months; measure changes in IPA, PBMC HDAC activity, SASP cytokine secretion, and epigenetic clocks.
• Mechanistic arm: Perform co‑IP, ChIP‑seq, and RNA‑seq on treated PBMCs to map PXR‑HDAC3 binding sites and transcriptional outcomes.

Falsifiability

If IPA does not predict epigenetic age change, or if PXR inhibition fails to modify IPA‑driven HDAC recruitment and SASP repression, the hypothesis is refuted. Likewise, a lack of interaction between PXR genotype and IPA‑epigenetic age associations would undermine the proposed causal pathway.

This framework extends existing correlative data by positioning IPA as an upstream regulator of chromatin state, directly linking microbiome metabolism to the molecular machinery of epigenetic aging.